Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment

Sleep Medicine Reviews

Volumn 17, Issue 2, 2013, Pages 153-159

  Verster, Joris C ^a   Roth, Thomas ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Anxiolytics; AUC; Benzodiazepine receptor agonist; Blood drug concentration; CNS; Driving; Driving impairment; Hypnotics; PK PD; SD; SDLP

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CLORAZEPATE; DIAZEPAM; FLUNITRAZEPAM; FLURAZEPAM; HYPNOTIC AGENT; LOPRAZOLAM; LORAZEPAM; LORMETAZEPAM; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; PLACEBO; SECOBARBITAL; TEMAZEPAM; ZOPICLONE;

ANXIETY DISORDER; CAR DRIVING; DRIVING ABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; INSOMNIA; OUTCOME ASSESSMENT; REVIEW; SIDE EFFECT; TRAFFIC ACCIDENT;

ANTI-ANXIETY AGENTS; AUTOMOBILE DRIVING; DIAZEPAM; GABA-A RECEPTOR AGONISTS; HUMANS; NORDAZEPAM; PSYCHOMOTOR PERFORMANCE;

EID: 84873440188     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2012.05.004     Document Type: Review

References (39)

1. Fell J.C., Voas R.B. The effectiveness of reducing illegal blood alcohol concentration (BAC) limits for driving: evidence for lowering the limit to .05 BAC. J Safety Res 2006, 37:233-243.
2. Louwerens J.W., Gloerich A.B.M., De Vries G., Brookhuis K.A., O'Hanlon J.F. The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high speed travel. Alcohol, drugs and traffic safety 1987, 183-192. Excerpta Medica, Amsterdam. P.C. Noordzij, R. Roszbach (Eds.).
3. Neutel C.I. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995, 5:239-244.
4. O'Hanlon J.F., Haak T.W., Blauw G.J., Riemersma J.B.J. Diazepam impairs lateral position control in highway driving. Science 1982, 217:79-81.
5. Verster J.C., Roth T. Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J General Med 2011, 4:359-371.
6. Verster J.C., Veldhuijzen D.S., Volkerts E.R. Is it safe to drive a car when treated with anxiolytics? Evidence from on-the-road driving studies during normal traffic. Curr Psychiatry Rev 2005, 1:215-225.
7. Verster J.C., Veldhuijzen D.S., Volkerts E.R. Residual effects of sleep medication on driving ability. Sleep Med Rev 2004, 8:309-325.
8. Verster J.C., Veldhuijzen D.S., Patat A., Olivier B., Volkerts E.R. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf 2006, 1:63-72.
9. O'Hanlon J.F., Vermeeren A., Uiterwijk M.M., Van Veggel L.M.A., Swijgman H.F. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies. Neuropsychobiology 1995, 31:81-88.
10. Verster J.C., Volkerts E.R., Verbaten M.N. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology 2002, 27:260-269.
11. Volkerts E.R., Brookhuis K.A., O'Hanlon J.F. Comparison of the effects of buspirone 5 mg and 10 mg, diazepam 5 mg, and lorazepam 1 mg (t.i.d.) upon actual driving performance 1987, Traffic Research Centre, University of Groningen, Report VK 87-02.
12. Brookhuis K.A., Borgman A.E. The effects of some anxiolytics on driving performance. J Drugtherapy Res 1988, 13:228-232.
13. Van Laar M.W., Volkerts E.R., Van Willigenburg A.P.P. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992, 12:86-95.
14. Van Laar M.W., Volkerts E.R., Verbaten M.N. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2a/2c antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology 2001, 2001(154):189-197.
15. Volkerts E.R., Abbink F., van Laar M.W., Tromp T.A., Maes R.A. Comparison of the effects of ritanserin 5 mg b.i.d. and lorazepam 1.5 mg b.i.d. upon driving performance in an over-the-road driving test 1988, Netherlands Institute for Drugs and Doping Research, Utrecht University, Technical report.
16. Leufkens T.R., Vermeeren A., Smink B.E., van Ruitenbeek P., Ramaekers J.G. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology 2007, 191:951-959.
17. Vermeeren A., O'Hanlon deClerck J.F., deClerck A.C., Kho L. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Therap 1995, 21:47-64.
18. Vermeeren A., Danjou P.E., O'Hanlon J.F. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 1998, 13:S98-S107.
19. Vermeeren A., Riedel W.J., van Boxtel M.P., Darwish M., Paty I., Patat A. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002, 25:224-231.
20. Verster J.C., Volkerts E.R., Schreuder A.H.C.M.L., Eijken E.J.E., van Heuckelum J.H.G., Veldhuijzen D.S., et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions and psychomotor performance. J Clin Psychopharmacol 2002, 22:576-583.
21. Leufkens T.R., Vermeeren A. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin Psychopharmacol 2009, 29:432-438.
22. Leufkens T.R., Lund J.S., Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009, 18:387-396.
23. Ramaekers J.G., Conen S., de Kam P.J., Braat S., Peeters P., Theunissen E.L., et al. Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology 2011, 215:321-332.
24. Mets M.A.J., de Vries J.M., de Senerpont Domis L.M., Volkerts E.R., Olivier B., Verster J.C. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance and mood in healthy adult subjects. Sleep 2011, 34:1327-1334.
25. O'Hanlon J.F., Volkerts E.R., de Vries G., van Arkel A., Wiethoff M., Meijer T. Flurazepam HCL's residual (hangover) effects upon actual driving performance 1983, Traffic Research Centre, University of Groningen, The Netherlands, Technical report VK 83-02.
26. Volkerts E.R., de Vries G., Meijer T., O'Hanlon J.F. Driving performance the day after use of loprazolam, flunitrazepam and placebo 1984, Traffic Research Centre, University of Groningen, The Netherlands, Technical report VK 83-04.
27. Volkerts E.R., Louwerens J.W., Gloerich A.B.M., Brookhuis K.A., O'Hanlon J.F. Zopiclone's residual effect upon actual driving performance versus those of nitrazepam and flunitrazepam 1984, Traffic Research Centre, University of Groningen, The Netherlands, Technical report VK 84-10.
28. O'Hanlon J.F., Volkerts E.R., Brookhuis K.A., Prins van Wijngaarden P., Buitenwerf T., de Vries G., Louwerens J.W. Repeated dose effects of nitrazepam and temazepam upon actual driving performance 1985, Traffic Research Centre, University of Groningen, The Netherlands, Technical report VK 85-02.
29. O'Hanlon J.F., Volkerts E.R. Hypnotics and actual driving ability. Acta Psychiatr Scand 1986, 74(Suppl. 332):95-104.
30. Brookhuis K.A., Volkerts E.R., O'Hanlon J.F. Repeated dose effects of lormetazepam and flurazepam upon driving performance. Eur J Clin Pharmacol 1990, 39(1):83-87.
31. Brookhuis K.A., Volkerts E.R., O'Hanlon J.F. Repeated dose effects of lormetazepam 1 and 2 mg (in soft gelatine capsules) and flurazepam 30 mg upon driving performance 1986, Traffic Research Centre, University of Groningen, The Netherlands, Technical report VK 86-18.
32. Volkerts E.R., van Laar M.W., van Willigenburg A.P.P., Maes R.A.A. A comparative study of on-the-road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg. Hum Psychopharmacol 1992, 7:297-309.
33. Volkerts E.R., Abbink F., van Laar M.W., Plomp T.A. A double-blind study to compare the acute residual effects of lormetazepam 1 mg, oxazepam 50 mg and placebo on driving performance in an over-the-road driving test 1989, NIDDR, University of Utrecht, The Netherlands, Technical report.
34. Weafer J., Fillmore M.T. Acute tolerance to alcohol impairment of behavioral and cognitive mechanisms related to driving: drinking and driving on the descending limb. Psychopharmacology 2012, 220:697-706.
35. Laurijssens B.E., Greenblatt D.J. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharm 1996, 30:52-76.
36. Verster J.C., Roth T. Thirty years of Dutch on-the-road driving research: strengths and limitations of the highway driving test and future challenges. Curr Psychopharmacol 2012, 1:97-102.
37. Verster J.C., Mets M.A.J. Psychoactive medication & traffic safety. Int J Environ Res Public Health 2009, 6:1041-1054.
38. Owens K., Ramaekers J.G. Drugs, driving, and models to measure driving impairment. Drugs, driving and traffic safety 2009, 43-58. Birkhauser Verlag AG, Basel, Switzerland. J.C. Verster, S.R. Pandi-Perumal, J.G. Ramaekers, J.J. de Gier (Eds.).
39. Verster J.C., Volkerts E.R., Johnson W., Liddicoat L. Zoplidem and traffic safety - the importance of treatment compliance. Curr Drug Saf 2007, 2:220-226.